SLG
SCLN

Stanley-Laman Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Stanley-Laman Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-87,882
Closed -$443K – 358
2013
Q4 		$443K Buy
+87,882
New +$423K 0.1% 145

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QBFM
QS Batterymarch Financial Management New York $3.78B AUM 22.02% 1-Year Est. Return

Stanley-Laman Group's SCLN Position: Q1 2014 in Review

Stanley-Laman Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2014, closing a stake of 87,882 shares — an estimated $443K sold.

Stanley-Laman Group first reported a position in SCLN in Q4 2013 and held it in 1 quarter. The position peaked at $443K in Q4 2013. 96 funds tracked by Wall St. Rank hold SCLN as of Q1 2014.

  • Stanley-Laman Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2014 after selling out during the quarter.
  • Stanley-Laman Group sold 87,882 Sciclone Pharmaceuticals Inc shares in Q1 2014, an estimated $443K.
  • Stanley-Laman Group first reported a position in Sciclone Pharmaceuticals Inc in Q4 2013 and held it in 1 quarter.
  • Stanley-Laman Group's Sciclone Pharmaceuticals Inc position peaked at $443K in Q4 2013.
  • 96 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2014.

Based on Stanley-Laman Group's 13F filing for Q1 2014, filed 11 Apr 2014.